ADHD
Help for children, adolescents, and adults.
Attention Deficit Hyperactivity Disorder, or ADHD, is the most common psychiatric disorder in children and adolescents, and a disorder that often significantly influences the lives of those affected into adulthood.
MEDICE is the market leader in Germany in the field of ADHD. Our preparations Medikinet® (tablets with 5, 10, 20 mg) and Medikinet® retard (active ingredient: methylphenidate hydrochloride, dose strengths 5, 10, 20, 30, 40, 50, 60 mg) developed by MEDICE have been successfully used for years to treat children and adolescents with ADHD - and not only nationally. Medikinet® retard (sometimes with other trade names) is now available in more than 25 countries. Since January 1, 2012, Attentin® - Germany's first and only dexamfetamine ready-to-use drug - has been available for children and adolescents age 6 and older, and who do not respond to methylphenidate.
After almost ten years of clinical research, MEDICE has set another milestone for ADHD therapy with Medikinet® adult: Medikinet® adult is the first MPH preparation approved in Germany for the treatment of adult ADHD patients. With the approval of Medikinet® adult (since 14.04.2011), a long existing care gap in Germany has been closed, and new perspectives in the treatment of ADHD in adulthood are opening up for doctors and patients.
With Kinecteen®, MEDICE has also been offering a 12-hour methylphenidate since April 1, 2017. It is available in four strengths 18mg, 27mg, 36mg and 54mg and can be prescribed at a fixed price.
Since mid-2019, Agakalin® - MEDICE's atomoxetine - completes the portfolio of ADHD. It is approved for children 6 years and older, adolescents and adults. Atomoxetine increases the available amount of the neurotransmitter norepinephrine in the brain. This chemical substance, which is naturally produced in the brain, increases attention in ADHD patients and reduces impulsivity and hyperactivity.
In the course of developing our field of expertise, we have gained a broad and deep understanding of ADHD through our commitment to the continuous optimization of therapeutic possibilities. The basis for this is, above all, the proximity to doctors, therapists, affected persons, and relatives. Personal contact and continuous, intensive exchanges have enabled us to fundamentally understand the disorder in all its facets. Within the framework of a multimodal treatment approach, ranging from medicinal measures to behavioral therapy interventions, and support for parents and educators, we develop solutions and services tailored to the individual needs of our physician partners and patients.
Experts and opinion leaders attest to MEDICE's great empathy for the challenges of treating ADHD. This is how we want to continue: To be able to provide an answer to every question.
